Idiopathic Pulmonary Fibrosis Clinical Trial
— IPFJESOfficial title:
Idiopathic Pulmonary Fibrosis Job Exposures Study
NCT number | NCT03211507 |
Other study ID # | 16SM3627 |
Secondary ID | |
Status | Completed |
Phase | |
First received | |
Last updated | |
Start date | May 1, 2017 |
Est. completion date | October 5, 2019 |
Verified date | December 2019 |
Source | Imperial College London |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
A case-control study to investigate whether job exposures are an under-recognized cause of idiopathic pulmonary fibrosis (IPF) using an interview to collect information about previous jobs and a blood test to investigate genetic susceptibility.
Status | Completed |
Enrollment | 960 |
Est. completion date | October 5, 2019 |
Est. primary completion date | October 5, 2019 |
Accepts healthy volunteers | No |
Gender | Male |
Age group | N/A and older |
Eligibility |
For cases Inclusion Criteria: - New diagnosis of IPF between February 2017 and October 2019 Exclusion Criteria: - Unable to give informed consent - Ever worked outside of the UK For controls Inclusion Criteria: - New outpatient department attendee between February 2017 and October 2019 Exclusion Criteria: - Unable to give informed consent - Ever worked outside of the UK (does not include work outside the UK by members of the armed forces or merchant navy) - Diagnosis of IPF |
Country | Name | City | State |
---|---|---|---|
United Kingdom | Imperial Healthcare NHS Trust | London |
Lead Sponsor | Collaborator |
---|---|
Imperial College London | Aberdeen Royal Infirmary, Aintree University Hospitals NHS Foundation Trust, Glasgow Royal Infirmary, Guy's and St Thomas' NHS Foundation Trust, Heart of England NHS Foundation Trust, Imperial College Healthcare NHS Trust, Morriston Hospital, Newcastle-upon-Tyne Hospitals NHS Trust, Norfolk and Norwich University Hospitals NHS Foundation Trust, North Bristol NHS Trust, Nottingham University Hospitals NHS Trust, Papworth Hospital NHS Foundation Trust, Portsmouth Hospitals NHS Trust, Royal Devon and Exeter NHS Foundation Trust, Royal Infirmary of Edinburgh, Taunton and Somerset NHS Foundation Trust, The Leeds Teaching Hospitals NHS Trust, University Hospital Birmingham NHS Foundation Trust, University Hospital of South Manchester, University Hospital Southampton NHS Foundation Trust, Wellcome Trust, Worcestershire Acute Hospitals NHS Trust |
United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Association between asbestos exposure and IPF | estimated using logistic regression for any vs no asbestos exposure and adjusting for age and smoking status | 2 years | |
Secondary | Dose-response relationship between asbestos exposure and IPF | estimated using logistic regression for categories of cumulative exposure and adjusting for age and smoking status | 2 years | |
Secondary | Gene-environment interaction (for MUC5B rs35705950 and asbestos exposure) odds ratio. | MUC5B rs35705950 and asbestos exposure odds ratio. | 2 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT05984992 -
The First-in-human Study of SRN-001 in Healthy Participants
|
Phase 1 | |
Active, not recruiting |
NCT04312594 -
Study of Jaktinib Hydrochloride Tablets in Participants With Idiopathic Pulmonary Fibrosis
|
Phase 2 | |
Recruiting |
NCT03865927 -
GKT137831 in IPF Patients With Idiopathic Pulmonary Fibrosis
|
Phase 2 | |
Completed |
NCT03979430 -
Early Detection of Acute Exacerbation in Patients With Idiopathic Lung Fibrosis - a Pilot Study
|
N/A | |
Enrolling by invitation |
NCT04905693 -
Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis
|
Phase 3 | |
Not yet recruiting |
NCT06241560 -
A Study in People With Idiopathic Pulmonary Fibrosis to Test Whether Pirfenidone Influences the Amount of BI 1015550 in the Blood
|
Phase 2 | |
Terminated |
NCT04419558 -
Zephyrus II: Efficacy and Safety Study of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)
|
Phase 3 | |
Completed |
NCT03725852 -
A Clinical Study to Test How Effective and Safe GLPG1205 is for Participants With Idiopathic Pulmonary Fibrosis (IPF)
|
Phase 2 | |
Terminated |
NCT03573505 -
An Efficacy and Safety Study of BG00011 in Participants With Idiopathic Pulmonary Fibrosis
|
Phase 2 | |
Recruiting |
NCT04148157 -
Quality of Life in IPF - Patient and Physician Perceptions
|
||
Completed |
NCT03222648 -
Structured Exercise Training Programme in Idiopathic Pulmonary Fibrosis
|
N/A | |
Not yet recruiting |
NCT06422884 -
A Phase 2 Trial of ENV-101 in Patients With Lung Fibrosis (WHISTLE-PF Trial)
|
Phase 2 | |
Completed |
NCT02257177 -
RCT (Randomized Control Trial) of TD139 vs Placebo in HV's (Human Volunteers) and IPF Patients
|
Phase 1/Phase 2 | |
Completed |
NCT02268981 -
Effects of an Oxymizer® During Daytime in Patients With Pulmonary Fibrosis (IPF)
|
N/A | |
Withdrawn |
NCT01524068 -
A MultiCenter Study of Combined PEX, Rituximab, and Steroids in Acute Idiopathic Pulmonary Fibrosis Exacerbations
|
Phase 2 | |
Enrolling by invitation |
NCT01382368 -
Acute Effect of Sildenafil on Exercise Tolerance and Functional Capacity in COPD, IPF and Post Pneumonectomy Patients
|
Phase 4 | |
Completed |
NCT01110694 -
Prospective Observation of Fibrosis in the Lung Clinical Endpoints Study
|
||
Completed |
NCT01199887 -
Trial Of IW001 in Patients With Idiopathic Pulmonary Fibrosis
|
Phase 1 | |
Active, not recruiting |
NCT02951416 -
Clinical Course of Interstitial Lung Diseases: European IPF Registry and Biobank
|
||
Terminated |
NCT00981747 -
Targeting Vascular Reactivity in Idiopathic Pulmonary Fibrosis
|
Phase 2/Phase 3 |